MHRA looks to add monetary sanctions to its enforcement options
This article was originally published in The Gold Sheet
Executive SummaryThe UK's Medicines and Healthcare products Regulatory Agency (MHRA) is considering adopting a new enforcement strategy that would cxpand the types of sanctions it can impose on pharmaceutical manufacturers
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.